ClinicalTrials.gg

TargetBeta

TNFRSF17

TNF receptor superfamily member 17 · also BCM, CD269, TNFRSF13A, BCMA · CD molecules

22 programs in company-led studies act on TNFRSF17, from 17 companies: 9 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (14 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
linvoseltamabruleRegeneron Pharmaceuticalsphase 41312 runningCD3ENCIt
teclistamabruleJohnson & Johnsonphase 41110 runningCD3ENCIt
elranatamabrulePfizerphase 4159 runningCD3ENCIt
belantamab mafodotinruleGlaxoSmithKlinephase 32518 running–NCIt
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 31212 runningCD19a judged reading
etentamigAbbViephase 31111 runningCD3Ethe company's pipeline
ramantamigJohnson & Johnsonphase 377 runningCD3E, GPRC5Da judged reading
anitocabtagene autoleucelruleGilead Sciencesphase 366 running–NCIt
equecabtagene autoleucelruleNanjing IASO Biotechnologyphase 354 running–NCIt
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 344 runningCD3Ethe company's pipeline
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 344 runningCD3E, GPRC5DNCIt
Evarucabgene AutoleucelruleNexcellaphase 322 running–NCIt
Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytesruleCartesian Therapeuticsphase 264 running–NCIt
cizutamigruleUCBphase 252 runningCD3ENCIt
belantamabGlaxoSmithKlinephase 232 running–the company's pipeline
vonsetamigruleRegeneron Pharmaceuticalsphase 232 runningCD3ENCIt
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 222 runningCD38, CD3Ethe company's pipeline
pamlectabart tismanitinruleHeidelberg Pharmaphase 222 running–NCIt
Allogeneic Anti-BCMA CAR T-cells AZD4045AstraZenecaphase 211 running–a judged reading
BCMA-CD19 Compound CAR T CellsruleiCell Gene Therapeuticsphase 133 runningCD19NCIt
LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010ruleKelonia Therapeuticsphase 111 runningCD3ENCIt
tunlucabtagene autoleucelBristol-Myers Squibbphase 111 runningGPRC5Da judged reading

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.